159 related articles for article (PubMed ID: 37310508)
21. miR-302a/b/c/d cooperatively inhibit BCRP expression to increase drug sensitivity in breast cancer cells.
Wang Y; Zhao L; Xiao Q; Jiang L; He M; Bai X; Ma M; Jiao X; Wei M
Gynecol Oncol; 2016 Jun; 141(3):592-601. PubMed ID: 26644266
[TBL] [Abstract][Full Text] [Related]
22. PI3-kinase/p38 kinase-dependent E2F1 activation is critical for Pin1 induction in tamoxifen-resistant breast cancer cells.
Lee KY; Lee JW; Nam HJ; Shim JH; Song Y; Kang KW
Mol Cells; 2011 Jul; 32(1):107-11. PubMed ID: 21573702
[TBL] [Abstract][Full Text] [Related]
23. A Novel Synthetic Dihydroindeno[1,2-b] Indole Derivative (LS-2-3j) Reverses ABCB1- and ABCG2-Mediated Multidrug Resistance in Cancer Cells.
Guo C; Liu F; Qi J; Ma J; Lin S; Zhang C; Zhang Q; Zhang H; Lu R; Li X
Molecules; 2018 Dec; 23(12):. PubMed ID: 30544754
[TBL] [Abstract][Full Text] [Related]
24. EGR3 and estrone are involved in the tamoxifen resistance and progression of breast cancer.
Xie Y; Han X; Yu J; Yuan M; Yan Y; Qin J; Lan L; Wang Y
J Cancer Res Clin Oncol; 2023 Dec; 149(20):18103-18117. PubMed ID: 37999751
[TBL] [Abstract][Full Text] [Related]
25. Involvement of the P2X7 receptor in the migration and metastasis of tamoxifen-resistant breast cancer: effects on small extracellular vesicles production.
Park M; Kim J; Phuong NTT; Park JG; Park JH; Kim YC; Baek MC; Lim SC; Kang KW
Sci Rep; 2019 Aug; 9(1):11587. PubMed ID: 31406126
[TBL] [Abstract][Full Text] [Related]
26. Induction of methionine adenosyltransferase 2A in tamoxifen-resistant breast cancer cells.
Phuong NT; Kim SK; Im JH; Yang JW; Choi MC; Lim SC; Lee KY; Kim YM; Yoon JH; Kang KW
Oncotarget; 2016 Mar; 7(12):13902-16. PubMed ID: 26418898
[TBL] [Abstract][Full Text] [Related]
27. Cold atmospheric plasma restores tamoxifen sensitivity in resistant MCF-7 breast cancer cell.
Lee S; Lee H; Jeong D; Ham J; Park S; Choi EH; Kim SJ
Free Radic Biol Med; 2017 Sep; 110():280-290. PubMed ID: 28666851
[TBL] [Abstract][Full Text] [Related]
28. Role of PTEN promoter methylation in tamoxifen-resistant breast cancer cells.
Phuong NT; Kim SK; Lim SC; Kim HS; Kim TH; Lee KY; Ahn SG; Yoon JH; Kang KW
Breast Cancer Res Treat; 2011 Nov; 130(1):73-83. PubMed ID: 21170675
[TBL] [Abstract][Full Text] [Related]
29. Ginsenoside Rg3 overcomes tamoxifen resistance through inhibiting glycolysis in breast cancer cells.
Zhao W; Ma J; Zhang Q; Zhang H; Ma W; Li S; Piao Y; Zhao S; Dai S; Tang D
Cell Biol Int; 2024 Apr; 48(4):496-509. PubMed ID: 38225685
[TBL] [Abstract][Full Text] [Related]
30. Developing multidrug-resistant cells and exploring correlation between BCRP/ABCG2 over-expression and DNA methyltransferase.
Ji N; Yuan J; Liu J; Tian S
Acta Biochim Biophys Sin (Shanghai); 2010 Dec; 42(12):854-62. PubMed ID: 21106767
[TBL] [Abstract][Full Text] [Related]
31. A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer.
Liu J; Li X; Wang M; Xiao G; Yang G; Wang H; Li Y; Sun X; Qin S; Du N; Ren H; Pang Y
Int J Oncol; 2018 Oct; 53(4):1601-1612. PubMed ID: 30066905
[TBL] [Abstract][Full Text] [Related]
32. Keratinocyte growth factor (KGF) regulates estrogen receptor-alpha (ER-alpha) expression and cell apoptosis via phosphatidylinositol 3-kinase (PI3K)/Akt pathway in human breast cancer cells.
Chang HL; Sugimoto Y; Liu S; Wang LS; Huang YW; Ye W; Lin YC
Anticancer Res; 2009 Aug; 29(8):3195-205. PubMed ID: 19661335
[TBL] [Abstract][Full Text] [Related]
33. Role of monocarboxylate transporter I/lactate dehydrogenase B-mediated lactate recycling in tamoxifen-resistant breast cancer cells.
Choi MC; Kim SK; Choi YJ; Choi YJ; Kim S; Jegal KH; Lim SC; Kang KW
Arch Pharm Res; 2023 Dec; 46(11-12):907-923. PubMed ID: 38048029
[TBL] [Abstract][Full Text] [Related]
34. SOX4-mediated FBW7 transcriptional upregulation confers Tamoxifen resistance in ER+ breast cancers via GATA3 downregulation.
Sharma A; Thacker G; Mishra M; Singh AK; Upadhyay V; Sanyal S; Trivedi AK
Life Sci; 2022 Aug; 303():120682. PubMed ID: 35662647
[TBL] [Abstract][Full Text] [Related]
35. Analysis of TLR2 in Primary Endocrine Resistant of Breast Cancer.
Wang Y; Wang G; Wang X; Yang J; Shen Y; Zhao B; Yang J
Front Biosci (Landmark Ed); 2024 Feb; 29(2):81. PubMed ID: 38420813
[TBL] [Abstract][Full Text] [Related]
36. UBR5 over-expression contributes to poor prognosis and tamoxifen resistance of ERa+ breast cancer by stabilizing β-catenin.
Yang Y; Zhao J; Mao Y; Lin G; Li F; Jiang Z
Breast Cancer Res Treat; 2020 Dec; 184(3):699-710. PubMed ID: 32914356
[TBL] [Abstract][Full Text] [Related]
37. Downregulated lncRNA ADAMTS9-AS2 in breast cancer enhances tamoxifen resistance by activating microRNA-130a-5p.
Shi YF; Lu H; Wang HB
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(4):1563-1573. PubMed ID: 30840279
[TBL] [Abstract][Full Text] [Related]
38. KLF4 overcomes tamoxifen resistance by suppressing MAPK signaling pathway and predicts good prognosis in breast cancer.
Jia Y; Zhou J; Luo X; Chen M; Chen Y; Wang J; Xiong H; Ying X; Hu W; Zhao W; Deng W; Wang L
Cell Signal; 2018 Jan; 42():165-175. PubMed ID: 28988130
[TBL] [Abstract][Full Text] [Related]
39. Deregulation of IGF-binding proteins -2 and -5 contributes to the development of endocrine resistant breast cancer in vitro.
Hawsawi Y; Humphries MP; Wright A; Berwick A; Shires M; Al-Kharobi H; El-Gendy R; Jove M; Twelves C; Speirs V; Beattie J
Oncotarget; 2016 May; 7(22):32129-43. PubMed ID: 27050076
[TBL] [Abstract][Full Text] [Related]
40. An in vitro model for the development of acquired tamoxifen resistance.
Guney Eskiler G; Cecener G; Tunca B; Egeli U
Cell Biol Toxicol; 2016 Dec; 32(6):563-581. PubMed ID: 27585693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
